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Abstract
Purpose A growing number of patients with brain metastases (BM) are being treated with stereotactic radiosurgery (SRS), and the
importance of evaluating the impact of SRS on the health-related quality of life (HRQoL) in these patients has been increasingly
acknowledged. This systematic review summarizes the current knowledge about the HRQoL of patients with BM after SRS.
Methods We searched EMBASE,Medline Ovid,Web-of-Science, the Cochrane Database, PsycINFOOvid, and Google Scholar
up to November 15, 2018. Studies in patients with BM in which HRQoL was assessed before and after SRS and analyzed over
time were included. Studies including populations of several types of brain cancer and/or several types of treatments were
included if the results for patients with BM and treatment with SRS alone were described separately.
Results Out of 3638 published articles, 9 studies met the eligibility criteria and were included. In 4 out of 7 studies on group
results, overall HRQoL of patients with BM remained stable after SRS. In small study samples of longer-term survivors, overall
HRQoL remained stable up to 12 months post-SRS. Contradictory results were reported for physical and general/global HRQoL,
which might be explained by the different questionnaires that were used.
Conclusions In general, SRS does not have significant negative effects on patients’ overall HRQoL over time. Future research is
needed to analyze different aspects of HRQoL, differences in individual changes in HRQoL after SRS, and factors that influence
these changes. These studies should take into account several methodological issues as discussed in this review.
Keywords Brainmetastases . Cancer . Health-related quality of life . Neoplasmmetastasis . Patient-reported outcomemeasures .
Radiosurgery
Background
Brain metastases (BM) originate from a malignancy outside
the central nervous system. Most patients diagnosed with BM
have primary lung cancer, breast cancer, or melanoma [1, 2].
Partly due to improved imaging such as MRI and improved
systemic treatment of the primary cancer, the number of pa-
tients with BM is increasing [3–7].
Traditionally, most patients with BM have been treated
with whole brain radiation therapy (WBRT) [3, 8, 9].
However, due to advances in the technology, and the increased
availability, of stereotactic radiosurgery (SRS) and concerns
about the long-term side effects of WBRT, radiation treatment
is shifting toward SRS [3, 10–12]. The high precision of SRS
spares healthy brain tissue, reducing the risks of long-term
side effects [13, 14]. Although SRS is usually delivered in
one fraction, it can be delivered in up to five fractions using
a linear accelerator, particle beam accelerator or multisource
Cobalt-60 unit [15].
Although the prognosis still remains poor [16–18], life ex-
pectancy in patients with BM is increasing due to improve-
ments in systemic treatments of the primary tumor [6, 19].
Therefore, maintaining a good health-related quality of life
(HRQoL) as long as possible is an important [20] primary
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objective in this patient group [21]. Consequently, manage-
ment of BM is no longer focused solely on survival, but also
on HRQoL and cognitive functioning of patients with BM
after treatment [22–24].
Authors of previous clinical studies and reviews concluded
that future trials that include patients with BM should assess
HRQoL as outcome measure, to inform clinical practice (e.g.,
make informed treatment decisions, assess the efficacy of
treatment, and inform patients about HRQoL over time) [21,
23–26]. In addition, HRQoL is important to evaluate as pa-
tients with BM rated HRQoL as the most important factor to
be considered in choosing among available treatment options
[27], as results from standard assessment of HRQoL in clinical
practice may help communication between patients and clini-
cians [28], and as HRQoL appears to be an independent prog-
nostic factor for survival [29–32].
To our knowledge, no systematic review has been conduct-
ed that focuses primarily on HRQoL outcomes after treatment
with SRS alone in patients with BM. A synthesis of the avail-
able research findings can help to better understand patients’
HRQoL over time after SRS and can provide directions for
future clinical trials. Ultimately, patients and physicians can be
better informed on what to expect after SRS in terms of
HRQoL. This systematic review summarizes the current




A systematic literature search was conducted to identify stud-
ies in which adult patients with BM were treated with SRS,
and HRQoL was assessed by means of a self-report question-
naire. EMBASE, Medline Ovid, Web-of-Science, the
Cochrane Database, PsycINFO Ovid, and Google Scholar
were searched up to November 15, 2018. Search terms were
verified, and search strategies were built and performed by a
biomedical information specialist of the library service of the
Erasmus Medical Center, The Netherlands. Studies had to be
published as empirical research articles in peer-reviewed
journals and written in English, German, or Dutch. Case-
report studies were excluded. Studies with an HRQoL assess-
ment before and at least one HRQoL assessment after SRS
alone were included. Within-group analyses had to be per-
formed on HRQoL data. Studies that included a heteroge-
neous sample of patients in terms of type of brain-involved
malignancies and/or studies in which different types of treat-
ment were evaluated, were included only if the results for
patients with BM treated with SRS alone were reported sepa-
rately. Inclusion and exclusion criteria in terms of PICOs
(patient, intervention, comparison, outcome) and search strat-
egies are presented in Online Resource 1.
Study selection
All studies were screened by the first author (E.V.) based on
title and abstract. If eligibility was not clear from the title and
abstract, the full text was screened. Papers that potentially met
the eligibility criteria after full text screening were also
reviewed by the second author (K.G.). Consensus was reached
in all cases. This review is a qualitative synthesis of empirical
studies. The same two authors extracted data from the includ-
ed studies and results were compared; there were no disagree-
ments. Reference lists of eligible articles were screened for
additional articles.
Assessment of included studies
Factors that were cross-checked and critically evaluated
among the studies included the following: type of cohorts/
study samples included (e.g., different histologies of primary
cancers), prior BM treatment, compliance or reasons for drop-
out reported, primary endpoints, HRQoL questionnaire used,




The systematic literature search identified 3638 unique re-
cords (Fig. 1). After screening title and abstract, 1290 full texts
were considered, and ultimately 9 studies were included in the
review (Table 1).
Characteristics of studies
All studies included a heterogeneous group of patients with
different primary histologies, except for one study [32], in
which only patients with primary lung cancer were included.
In one study [40], only geriatric patients (age ≥ 70) were
included. In one other study [39], patients were included
who already received 3 courses of SRS, whereas in most stud-
ies, patients were included before their first course of SRS.
Baseline characteristics of patients with baseline HRQoL
scores were not reported in two studies [39, 40]. For two
studies [33, 36], a proportion of patients was also included
in a subsequent study (respectively [32, 37]). Sample sizes
in the 9 selected studies ranged from 15 to 97 patients. In most
studies, patients were female (range 43.2 to 67.3%), had pri-
mary lung cancer (range 37.3 to 100%), and had a median
Karnofsky Performance Status (KPS) score of 80 (range <
Support Care Cancer
70 to 100) (Table 1). In four studies [34–37], patients with
newly diagnosed BM were included; in four other studies
[32, 33, 38, 39], patients received prior BM treatment; and
in one study [40], it was not reported if patients received prior
BM treatment. Reasons for dropout were not reported in 6
studies [32, 34, 35, 38–40], and in two studies [36, 37], rea-
sons of dropout were reported, but without the numbers of
patients (Table 1).
HRQoL assessments
Results on HRQoL over time of all reviewed studies are pre-
sented in Table 1. In three [32, 33, 38] out of nine studies,
HRQoL was the primary outcome measure. Four studies [32,
33, 38, 39] evaluated HRQoL both at the group level and at
the individual level, two studies [35, 36] evaluated HRQoL at
the group level only, and two studies [34, 37] evaluated
HRQoL at the individual level only. In the studies reviewed,
HRQoL was measured with 5 different self-report question-
naires. The most frequently used questionnaire was the brain
cancer–specific Functional Assessment of Cancer Therapy
Brain (FACT-Br), used in 4 studies (Table 2). The most com-
monly investigated aspects of HRQoL at the group level were
physical, general/global, social, and emotional aspects. In six
studies [32–37], cancer-specific HRQoL self-report question-
naires were used to measure HRQoL, and in three studies
[38–40], generic HRQoL self-report questionnaires were used
to measure HRQoL. In two studies [34, 38], an unknown
number of patients completed the “pretreatment”/baseline
HRQoL measurement after SRS. Follow-up questionnaires
were sent by mail in two studies [32, 33], and in the other
studies, administration was scheduled to coincide with hospi-
tal visits after SRS. In five studies [34, 36–39], mean HRQoL
scores during follow-up were not reported, although in two of
them [38, 39], mean HRQoL at patients’ last follow-up were
reported (this point is not the same for each patient).
Discussion
The aim of this review was to summarize findings of studies
on (changes in) the HRQoL of patients with BM after SRS.
Nine studies were included. Conclusions on HRQoL after
SRS however should be drawn with caution, as several
(methodological) limitations (discussed below) complicate
the interpretation of findings. In two studies on individual
scores only, stable overall HRQoL was demonstrated in most
patients [34, 37]. In four out of seven studies evaluating group
scores, overall HRQoL remained stable in patients with BM
after SRS [32, 33, 35, 36], even up to 12 months after SRS in
small groups of long-term survivors [32, 33]. However, the
three other studies found a decline in overall HRQoL after
SRS. One of these studies reported a decline in overall
HRQoL 6 and 12 months after treatment in an otherwise un-
defined small subgroup of geriatric patients (age ≥ 70) [40],
and two other studies reported a statistically significant de-
cline in overall HRQoL at patients’ last follow-up [38, 39].


























(n = 3638) 
Records excluded 
(n = 2348) 
Full text articles assessed for 
eligibility (n = 1290) 
Full text articles excluded, with reasons (n = 1281): 
No (self-report) HRQoL measure (n = 558) 
 No full text published (n = 365) 
No empirical article, e.g., review, protocol, editorial (n = 184) 
No SRS (alone) treatment group (n = 106) 
 No English, German, or Dutch Language (n = 29) 
No brain metastases (n = 18) 
Case report (n = 9) 
No within-group analyses on HRQoL data (n = 5) 
No (pre- and/or post-treatment) HRQoL data reported (n = 4) 
No pretreatment HRQoL measurement (n = 3) Studies included in qualitative 
synthesis (n = 9) 
Records identified through database searching 
(n = 5244) 
Records after duplicates removed 
(n = 3638) 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































These last two studies [38, 39] most likely assessed
HRQoL at the point of progressive disease for many patients,
as no further follow-up assessments could be completed. As
several studies report a decline in HRQoL after progressive
disease [31, 33, 36, 41, 42], the occurrence of progressive
disease might explain why these two studies found a decline
in HRQoL while other studies reported stable HRQoL during
multiple follow-up assessments. Differences in negative and
stable outcomes might also be due to different patient or treat-
ment characteristics. In one of these studies [39], patients
underwent a minimum of three SRS courses before inclusion
and patient characteristics were not reported. However, base-
line patient and treatment characteristics in the other study
[38] were comparable with the baseline characteristics in the
studies reporting stable HRQoL after SRS [32, 33, 35, 36].
Although HRQoL scores on the group level appear to re-
main stable over time, they may mask individual changes in
HRQoL. Habets et al. [36] reported stable HRQoL over time
on the group level, while analysis of individual results from a
portion of the same study sample on a selection of the scales
by van der Meer et al. [37] showed that most patients demon-
strated both improvements as well as deterioration in different
aspects of HRQoL over time. Four other studies [32, 33, 38,
39] evaluated both group and individual changes in HRQoL
after SRS. Two studies found stable mean group scores on
additional concerns over time, while on the individual level,
the majority of patients (60%) reported less additional
concerns [32] and small groups of patients (23 to 36%) report-
ed more additional concerns 1 month after SRS [32, 33]. Two
other studies that investigated HRQoL at patients’ last follow-
up (median HRQoL follow-up 12 and 19 months) found a
decline in group scores on overall health state and self-per-
ceived health state, whereas on the individual level, similar
and substantial percentages of patients improved (overall
health state, 24% versus 45%; and self-perceived health state,
41% versus 45%) and declined (overall health state, 28%
versus 48%; and self-perceived health state, 50% versus
54%) [38, 39]. Differences in the percentages of improved
and declined overall health states between both studies may
be explained by chance due to the small sample size (n = 27)
in one of these studies [39]; in addition, patients in this study
had already undergone a minimum of three SRS courses be-
fore inclusion in the study.
Similarly, combining the multidimensional aspects of
HRQoL, including physical, social, and emotional function-
ing [43], into a single overall HRQoL score may also lead to a
loss of information or mask potential improvements and de-
clines in more specific aspects of HRQoL. One study [34]
evaluated an overall HRQoL score only, limiting conclusions
about the full range of potentially different HRQoL effects.
However, preselecting certain HRQoL subscales based on
existing literature and/or clinical insights is a more conserva-









































































































































































































































































































































































































































































































































































































































outcomes which might lead to potential problems with type I
errors in statistical testing due to multiple comparisons.
At the group level, the most frequently evaluated aspects of
HRQoL were physical, general/global, social, and emotional
aspects. Mean scores of these aspects remained stable over
time [32, 33, 35, 36], except for physical well-being/function-
ing and general/global HRQoL. On these aspects, contradic-
tory results were reported. Three studies using the EORTC-
QLQ-C30 or EQ-5D reported a decline in the physical aspect
of HRQoL [36, 38, 39], while 3 other studies using the FACT-
Br reported stable scores over time [32, 33, 35]. This can be
explained by the different questionnaires that were used. For
example, the subscale physical functioning of the EORTC-
QLQ-C30 and the subscales mobility, self-care, and usual-
activities of the EQ-5D are more focused on physical
activities, while the subscale physical well-being of the
FACT-Br is more focused on physical symptoms. It should
be noted in addition that declines were reported by the two
studies in which HRQoL was assessed at a patients’ last fol-
low-up. This might also explain the difference in findings
among studies on general/global HRQoL; the two studies
measuring HRQoL at patients’ last follow-up reported a de-
cline [38, 39], while four other studies reported stable scores
[32, 33, 35, 36]. However, the different setup in questionnaires
might also play a role. Since there is no standard assessment
tool for HRQoL in patients with BM, comparing results from
studies using different HRQoL measurements remains a chal-
lenge [23, 24].
It should be noted that in two studies [34, 38] an unknown
number of patients completed the pretreatment HRQoL mea-
surement after SRS, which may have affected conclusions on
HRQoL over time. In addition, in five studies [34–37, 40],
previous treatments directed at the BM could have negatively
affected the HRQoL of the patients. In two studies [32, 33],
follow-up questionnaires were sent by mail; consequently, it
was not known whether patients completed the self-report
questionnaire themselves without the influence of significant
others. On the other hand, patients could fill out these ques-
tionnaires at home, which may cause less stress or anxiety
compared with the other studies, in which questionnaires were
administered in the hospital at control visits, and thus provide
a more realistic representation of HRQoL in daily life.
Among the other methodological limitations of studies on
HRQoL after SRS was the lack of (reporting of) within-group
analyses. To investigate changes in HRQoL after SRS, within-
group analyses are needed to be able to draw conclusions on
the effect of SRS onHRQoL over time. Unfortunately, several
studies did not perform such analyses or did not report the
results [31, 42, 44–46] and were therefore not included in this
review.
When interpreting results from longitudinal studies on
HRQoL after SRS, it is important to be aware that a range of
other factors, besides the treatment of interest, may influence
HRQoL over time, including medication use (e.g., steroids),
effects of treatment for the primary tumor (including chemo-
therapy, immunotherapy, radiation, surgery), pseudo-
progression or progression of disease, HRQoL before treat-
ment, cognitive symptoms, and the mere passage of time. For
example, low mood after the diagnosis of BM may be allevi-
ated by the use of an antidepressant or just passage of time. In
four of the included studies, factors that affected (changes in)
HRQoL after SRS were evaluated. These studies suggested
that HRQoL after SRS was associated with KPS, total tumor
volume in the brain, symptomatic BM, time since SRS, and
disease progression (e.g., intra- and extracranial tumor activi-
ty) [32, 33, 36, 38], while the number of BM, sex, and age did
not appear to influence HRQoL [32, 33, 36]. However, due to
differences between these studies in statistical techniques
employed (univariate and multivariate), differences in the
choice as to which predictors were investigated and at which
time points, it was not possible to draw reliable conclusions.
In addition, a potential effect of “response shift” should be
considered. A response shift refers to changes in patients’
internal standards, values, and conceptualization of HRQoL
that may occur during the course of their disease [47–50].
Studies have shown that although the clinical health status
of patients with cancer might deteriorate considerably over
time, HRQoL scores often remain stable [47]. Most of the
studies reviewed did not find considerable deterioration of
HRQoL, which may be (partly) explained by the response
shift phenomenon. However, although patients might have
shifted their response pattern over time, their self-reported
HRQoL may still reflect their actual personal interpretation
of their HRQoL at a given point in time [51].
High attrition and low response rates are very common in
studies that include patients whose life expectancy is short
[24, 48, 52]. In many of the studies reviewed, the number of
patients completing (long-term) follow-up assessments
dropped substantially. In most studies, reasons for dropout
(e.g., decease, disease progression, personal motivation) were
not or only partly described [32, 34–40]. As a result, interpre-
tation of results is complicated [48], and results might not be
generalizable to the whole population of patients [53].
However, if the reasons for dropout are related to the disease
(progression or death), rather than personal motivation, the
results still are very informative with respect to the subgroup
of patients who survive on the longer term. Reporting the
reasons for dropout is therefore very important for proper
interpretation of study results.
The timing of follow-up measurements varied across the
studies reviewed and only 3 studies [32, 33, 40] had follow-up
periods longer than 6 months; in two other studies [38, 39],
HRQoL was assessed at last follow-up, which differed for
each patient.
Several limitations of the review process should be noted as
well. Abstract screening was carried out by only one author,
Support Care Cancer
and thus, we cannot rule out the possibility that one or more
additional relevant articles might have been identified if an-
other author had been involved in this screening process.
However, we believe that the screening process as carried
out was very thorough. It is also possible that relevant studies
were excluded due to language constraints. A risk of publica-
tion bias cannot be ruled out, since, for example, gray litera-
ture was not included in this review.
Future research
The synthesis of the findings of the nine relevant studies re-
vealed that future clinical trials on the effects of SRS on
HRQoL of patients with BM are needed to further investigate
the multiple aspects of HRQoL over time, individual changes
in HRQoL after treatment, and factors that influence HRQoL.
Studies should report within-group changes and clearly de-
scribe statistical analyses and reasons for dropout. For the
assessment of HRQoL in this patient population, brain
cancer–specific self-report HRQoL questionnaires, evaluating
the different aspects of HRQoL, should be used. To minimize
patient burden and therefore prevent high dropout rates, ded-
icated personnel should be available to administer HRQoL
questionnaires, and follow-up HRQoL assessments should
be scheduled to coincide with and take place before, instead
of after, standard hospital visits after SRS [48, 54]. In addition,
more studies with adequate sample sizes at long-term follow-
ups (e.g., > 6 months) are needed to analyze different aspects
of HRQoL at these time points, especially because irreversible
and progressive radiation-induced brain injury, including cog-
nitive impairment, usually emerges > 6 months after treatment
[55, 56]. There are many methodological and logistical chal-
lenges in performing serial HRQoL assessments in these pa-
tients, but the payoff in terms of increased understanding of
the effect of both the disease and its treatment on the function-
al health, symptom burden, and well-being of our patients
justifies the additional investment required.
Relevance for clinical practice
HRQoL appears to be an independent prognostic factor for
survival in cancer patients with and without BM [29–32],
and in a recent study [27], HRQoL was rated by patients with
BM as the most important factor to be considered in choosing
among available treatment options. Since more patients with
multiple BM are treated with SRS, it is important to know how
this treatment may affect the HRQoL of patients over time. In
general, results of the studies reviewed here suggest that SRS
does not have a significant negative effect on patients’ overall
HRQoL over time (even up to 12 months after SRS). This
indicates that, in terms of HRQoL, SRS can be safely used
in the management of patients with BM. Although more re-
search is needed on factors influencing HRQoL of patients
with BM, the current evidence suggests that clinicians should
pay additional attention to patients with low KPS, large tumor
volumes, symptomatic BM, and disease progression. In addi-
tion, assessment of HRQoL in clinical practice may improve
communication between patients and clinicians, is helpful to
identify patients’ concerns [28], and helps clinicians to pro-
vide patients with personalized information. This emphasizes
the importance of incorporating HRQoL measures as a stan-
dard part of clinical care in patients with BM.
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